|
| 36917886 | Fully human monoclonal antibody targeting activated ADAM10 on colorectal cancer cells. | Biomed Pharmacother | 2023 |
| 38019654 | Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability. | Cell Rep | 2023 |
| 37700833 | Editorial: Therapeutic antibody domains against cancer. | | 2023 |
| 37774704 | Preclinical development of a chimeric antigen receptor TÂ cell therapy targeting FGFR4 in rhabdomyosarcoma. | Cell Rep Med | 2023 |
| 37771390 | Preclinical assessment of a novel human antibody VH domain targeting mesothelin as an antibody-drug conjugate. | Mol Ther Oncolytics | 2023 |
| 36761762 | Human antibodies targeting ENPP1 as candidate therapeutics for cancers. | Front Immunol | 2023 |
| 37265667 | Rapid Emergence of Potentially Transmissible Severe Acute Respiratory Syndrome Coronavirus 2 With Resistance to Combination Monoclonal Antibody Therapy. | | 2023 |
| 37067377 | Human Antibody V Domains Targeting GPNMB and VCAM-1 as Candidate Therapeutics for Cancers. | | 2023 |
| 36864545 | Development of an efficient method for selection of stable cell pools for protein expression and surface display with Expi293F cells. | | 2023 |
| 36862515 | COVID-19 convalescent plasma boosts early antibody titer and does not influence the adaptive immune response. | JCI Insight | 2023 |
| 36923424 | Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates. | | 2023 |
| 34582565 | Adcitmer , a new CD56-targeting monomethyl auristatin E-conjugated antibody, is a potential therapeutic approach in Merkel cell carcinoma. | British Journal of Dermatology | 2022 |
| 35464476 | Construction of a Large Size Human Immunoglobulin Heavy Chain Variable (VH) Domain Library, Isolation and Characterization of Novel Human Antibody VH Domains Targeting PD-L1 and CD22. | Frontiers in Immunology | 2022 |
| 36345941 | In vivo killing of primary HIV-infected cells by peripheral-injected early memory-enriched anti-HIV duoCAR T cells. | JCI Insight | 2022 |
| 35877472 | FGFR4-Targeted Chimeric Antigen Receptors Combined with Anti-Myeloid Polypharmacy Effectively Treat Orthotopic Rhabdomyosarcoma. | Mol Cancer Ther | 2022 |
| 35875685 | Potent and broad neutralization of SARS-CoV-2 variants of concern (VOCs) including omicron sub-lineages BA.1 and BA.2 by biparatopic human VH domains. | iScience | 2022 |
| 35482198 | Yeast Mating as a Tool for Highly Effective Discovery and Engineering of Antibodies via Display Methodologies. | Methods in Molecular Biology | 2022 |
| 35982054 | SARS-CoV-2 variants of concern: spike protein mutational analysis and epitope for broad neutralization. | Nature Communications | 2022 |
| 36400786 | Cancer cell survival depends on collagen uptake into tumor-associated stroma. | Nature Communications | 2022 |
| 35399718 | An insulin growth factor-I/II-neutralizing monoclonal antibody in combination with epidermal growth factor receptor inhibitors potently inhibits tumor cell growth. | Journal of Cancer | 2022 |
| 36460335 | GPC2 antibody-drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies. | J Immunother Cancer | 2022 |
| 34740610 | A highly-specific fully-human antibody and CAR-T cells targeting CD66e/CEACAM5 are cytotoxic for CD66e-expressing cancer cells in vitro and in vivo. | Cancer Lett | 2022 |
| 35272105 | Functional reconstitution of the MERS CoV receptor binding motif. | Molecular Immunology | 2022 |
| 34971569 | GPC2-CAR TÂ cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. | Cancer Cell | 2022 |
| 35194603 | Potent Neutralization of Omicron and other SARS-CoV-2 Variants of Concern by Biparatopic Human VH Domains. | bioRxiv | 2022 |
| 35174992 | Design of a Novel Fab-Like Antibody Fragment with Enhanced Stability and Affinity for Clinical use. | Small Methods | 2022 |
| 35136050 | Structural and biochemical rationale for enhanced spike protein fitness in delta and kappa SARS-CoV-2 variants. | Nature Communications | 2022 |
| 34768098 | Inhibitory monoclonal antibody targeting ADAM17 expressed on cancer cells. | Translational Oncology | 2022 |
| 34601396 | Effective killing of cells expressing CD276 (B7-H3) by a bispecific T cell engager based on a new fully human antibody. | Translational Oncology | 2021 |
| 34021002 | Proteomic Screens for Suppressors of Anoikis Identify IL1RAP as a Promising Surface Target in Ewing Sarcoma. | Cancer Discov | 2021 |
| 33914735 | Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies. | PLoS Biology | 2021 |
| 34273351 | Structural details of monoclonal antibody m971 recognition of the membrane-proximal domain of CD22. | Journal of Biological Chemistry | 2021 |
| 34107549 | The reduced form of the antibody CH2 domain. | Protein Sci | 2021 |
| 34095859 | Protocol for constructing large size human antibody heavy chain variable domain (V) library and selection of SARS-CoV-2 neutralizing antibody domains. | STAR Protocols | 2021 |
| 33762438 | Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models. | Science Translational Medicine | 2021 |
| 34337560 | A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope. | Cell Rep Med | 2021 |
| 33203700 | Folate Receptor Beta Designates Immunosuppressive Tumor-Associated Myeloid Cells That Can Be Reprogrammed with Folate-Targeted Drugs. | Cancer Res | 2021 |
| 33325681 | Developability Assessment of an Isolated C2 Immunoglobulin Domain. | Analytical Chemistry | 2021 |
| 34681796 | Human Antibody Domains and Fragments Targeting Neutrophil Elastase as Candidate Therapeutics for Cancer and Inflammation-Related Diseases. | International Journal of Molecular Sciences | 2021 |
| 34465595 | Antibody-Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization. | Molecular Cancer Therapeutics | 2021 |
| 34914928 | Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding. | Cell Reports | 2021 |
| 34732890 | Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs. | Nature | 2021 |
| 32941803 | High Potency of a Bivalent Human V<sub>H</sub> Domain in SARS-CoV-2 Animal Models. | Cell | 2020 |
| 32027842 | Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study. | Lancet Infectious Diseases, The | 2020 |
| 31795802 | An engineered human IgG1 CH2 domain with decreased aggregation and nonspecific binding. | mAbs | 2020 |
| 32544372 | Potent neutralization of SARS-CoV-2 by human antibody heavy-chain variable domains isolated from a large library with a new stable scaffold. | MAbs | 2020 |
| 32591411 | Interaction with CD68 and Regulation of GAS6 Expression by Endosialin in Fibroblasts Drives Recruitment and Polarization of Macrophages in Hepatocellular Carcinoma. | Cancer Research | 2020 |
| 33139569 | Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection. | Proc Natl Acad Sci U S A | 2020 |
| 32860752 | Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies. | Cancer Cell | 2020 |
| 32908002 | Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade. | Sci Transl Med | 2020 |